Vanguard Global Advisers
MAZE

Vanguard Global Advisers’s Maze Therapeutics MAZE Stock Holding History

Vanguard Global Advisers’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$330K Sell
11,055
-4,147
-27% -$109K ﹤0.01% 2289
2026
Q1 		$454K Buy
+15,202
New +$671K ﹤0.01% 2091

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Vanguard Global Advisers's MAZE Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Maze Therapeutics (MAZE) stake by 27% in Q2 2026, selling an estimated $109K and leaving 11,055 shares worth $330K. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

Vanguard Global Advisers first reported a position in MAZE in Q1 2026 and has held it in 2 quarters since. The position peaked at $454K in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Vanguard Global Advisers held 11,055 shares of Maze Therapeutics worth $330K as of Q2 2026.
  • Vanguard Global Advisers sold 4,147 Maze Therapeutics shares in Q2 2026, an estimated $109K.
  • Maze Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2289 holding.
  • Vanguard Global Advisers first reported a position in Maze Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Maze Therapeutics position peaked at $454K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.